Drug-risk communication to pharmacists: assessing the impact of risk-minimization strategies on the practice of pharmacy

J Am Pharm Assoc (2003). 2008 Jul-Aug;48(4):494-500. doi: 10.1331/JAPhA.2008.07045.

Abstract

Objectives: To gain insight on the knowledge, opinions, barriers, and practices of pharmacists regarding drug risk-minimization tools.

Design: Descriptive, nonexperimental, cross-sectional survey.

Setting: 20 states in the United States, fall 2004.

Participants: 2,052 randomly selected licensed pharmacists employed in a position requiring an active pharmacist license at the time of the survey and who responded to the survey.

Intervention: Participants completed a four-page survey regarding their experience with different types of risk-minimization tools.

Main outcome measure: Univariate distributions for each question were analyzed.

Results: 50% of survey recipients responded to the mailing; 88% of respondents had an active pharmacist license. Of respondents, 18% reported never having received a Dear Healthcare Professional letter and 29% stated that they were not familiar with Medication Guides. Patient package inserts were thought to be somewhat effective by 53% of respondents. Of pharmacists who dispensed a drug with programs for special stickers to be affixed on prescriptions to indicate that the labeled risk had been addressed by the prescriber, 41% reported receiving a prescription without a sticker; 45% dispensed the prescription when stickers were missing. Sixty percent of pharmacists stated that risk-minimization programs have a negative impact on the daily practice of pharmacy; nevertheless, many acknowledged that it was a necessary duty.

Conclusion: Pharmacists might benefit from additional training on risk-minimization strategies. The successful implementation and impact of risk-minimization programs on the practice of pharmacy should be carefully considered by drug manufacturers and regulators.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Communication
  • Cross-Sectional Studies
  • Data Collection
  • Drug-Related Side Effects and Adverse Reactions*
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Pharmaceutical Services / organization & administration*
  • Pharmacists / organization & administration*
  • Professional Role
  • Risk Management / methods*
  • United States